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A B S T R A C T
Parkinson's disease (PD) is a progressive neurological disorder, mainly characterized by the progressive loss of
dopaminergic neurons in the Substantia nigra pars compacta (SNpc) and by the presence of intracellular inclu-
sions, known as Lewy bodies. Despite SNpc being considered the primary affected region in PD, the neuro-
pathological features are confined solely to the nigro-striatal axis. With disease progression other brain regions
are also affected, namely the cerebral cortex, although the spreading of the neurologic damage to this region is
still not completely unraveled.
Tauroursodeoxycholic acid (TUDCA) is an endogenous bile acid that has been shown to have antioxidant
properties and to exhibit a neuroprotective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice
model of PD. Moreover, TUDCA anti-inflammatory properties have been reported in glial cells, making it a
prominent therapeutic agent in PD.
Here, we used C57BL/6 mice injected with MPTP in a sub-acute paradigm aiming to investigate if the neu-
rotoxic effects of MPTP could be extended to the cerebral cortex. In parallel, we evaluated the anti-oxidant,
neuroprotective and anti-inflammatory effects of TUDCA. The anti-inflammatory mechanisms elicited by TUDCA
were further dissected in microglia cells.
Our results show that MPTP leads to a decrease of ATP and activated AMP-activated protein kinase levels in
mice cortex, and to a transient increase in the expression of antioxidant downstream targets of nuclear factor
erythroid 2 related factor 2 (Nrf-2), and parkin. Notably, MPTP increases pro-inflammatory markers, while
down-regulating the expression of the anti-inflammatory protein Annexin-A1 (ANXA1). Importantly, we show
that TUDCA treatment prevents the deleterious effects of MPTP, sustains increased levels of antioxidant enzymes
and parkin, and most of all negatively modulates neuroinflammation and up-regulates ANXA1 expression.
Additionally, results from cellular models using microglia corroborate TUDCA modulation of ANXA1 synthesis,
linking inhibition of neuroinflammation and neuroprotection by TUDCA.
1. Introduction
Parkinson's disease (PD) is the second most common neurodegen-
erative disorder, affecting about 3% of the population over 65 years of
age and 0.3% of the overall worldwide population (Pringsheim et al.,
2014). PD is mainly a motor disorder, pathologically characterized by
the loss of dopaminergic neurons in the Substantia nigra pars compacta
(SNpc), severe striatal dopamine depletion, and by the presence of in-
tracellular inclusions containing aggregates of α-synuclein known as
Lewy bodies (Goedert et al., 2013; Przedborski, 2005).
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Despite extensive research, the mechanisms underlying neuro-
pathology of PD are still largely unknown. However, it is believed that
multiple genetic and environmental factors play critical roles in the
development of the disease. The study of familial forms of PD, gave a
decisive contribution to the unraveling of the molecular pathways in-
volved in dopaminergic cell loss, including α-synuclein proteostasis,
mitochondrial dysfunction, oxidative stress, and neuroinflammation
(Blesa et al., 2015; Klein and Westenberger, 2012; Moon and Paek,
2015; Niranjan, 2014).
The involvement of mitochondrial dysfunction in PD was reinforced
by the discovery that exposure to 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP) a selective inhibitor of mitochondrial Complex I,
leads to parkinsonism and degeneration of dopaminergic neurons in
humans and in animal models of the disease (Fabre et al., 1999; Nicklas
et al., 1985; Rosa et al., 2018). In accordance, post mortem studies in PD
patients brains showed reduced Complex I activity and increased re-
active oxygen species (ROS) production (Hwang, 2013). Several mu-
tations in familial PD also reaffirm the implication of mitochondrial
dysfunction in this disease. For example, half of familial PD cases, and
about 20% of the cases with early onset, are associated with loss-of-
function mutations in the PARK2 gene. This gene encodes for parkin, a
component of an E3 ubiquitin ligase complex, with an important role in
the modulation of different aspects of mitochondrial turnover and
homeostasis (Martin et al., 2011; Klein and Westenberger, 2012;
Thomas and Flint, 2007).
Neuroinflammation involvement in PD pathogenesis was proven by
the presence of reactive microglia and astrocytes, as well as increased
levels of cytokines and pro-inflammatory enzymes in PD patients brains
(McGeer et al., 1988; Mogi et al., 1994; Blum-Degen et al., 1995; Muller
et al., 1998; Miklossy et al., 2006; Hirsch and Hunot, 2009; Liddelow
et al., 2017). Moreover, serum and cerebrospinal fluid from PD pa-
tients, showed increased levels of cytokines (Hirsch and Hunot, 2009),
further supporting an inflammatory contribution to the phenotype of
this disease. We and others have also described the presence of reactive
glia and pro-inflammatory mediators in both mouse and monkey ex-
perimental PD models (Hurley et al., 2003; Liberatore et al., 1999; Rosa
et al., 2018).
PD studies are generally focused in the loss of dopaminergic neurons
in the nigro-striatal axis. However, other brain areas are also affected in
this disorder. In early stages, neuron loss is thought to be confined to
the ventrolateral substantia nigra leaving other midbrain areas exempt,
though it becomes more widespread by the end-stage of the disease
(Dauer and Przedborski, 2003; Poewe et al., 2017). However, the
spread of the neurologic insult to other brain regions besides the nigro-
striatal axis is still not completely characterized. Therefore, under-
standing the broader damage, as well as the effects of therapeutic
strategies in other areas is essential to fully characterize the pathogenic
mechanisms involved in PD.
The discovery of new pharmacological approaches capable to delay,
stop or revert neurodegeneration and PD progression are an urgent
matter. Tauroursodeoxycholic acid (TUDCA) is an endogenous hydro-
philic bile acid formed in the liver by conjugation of ursodeoxycholic
acid (UDCA) with taurine. TUDCA is quickly bioavailable via oral,
subcutaneous, or intravenous administration, has no associated toxicity
and crosses the blood brain barrier (Ackerman and Gerhard, 2016;
Rodrigues et al., 2002). Importantly, we showed that TUDCA treatment
effectively prevented/ameliorated motor impairments of mice injected
with MPTP (Rosa et al., 2018). Moreover, TUDCA also displayed an
anti-inflammatory role by decreasing glia activation and pro-in-
flammatory markers expression while preventing the MPTP-induced
decrease of annexin-A1 (ANXA1), prevented dopaminergic cell loss,
mitochondrial dysfunction, ROS production and increased the expres-
sion of antioxidant enzymes in MPTP-injected mice midbrain and
striatum (Castro-Caldas et al., 2012; Moreira et al., 2017; Rosa et al.,
2017; Rosa et al., 2018).
Herein we used a sub-acute paradigm of MPTP administration in
mice aiming to investigate if the neurotoxic effects, as well as the
neuroprotection afforded by TUDCA, are extended to the cerebral
cortex. In addition, we addressed the ability of TUDCA to modulate
ANXA1 expression, in the cerebral cortex and in microglia cells, as part
of its anti-inflammatory mechanisms.
2. Material and methods
2.1. Ethics statement
All procedures were conducted in accordance with European reg-
ulations (European Union Directive 2010/63/EU). Animal facilities and
the people directly involved in animal experiments were certified by the
Portuguese regulatory entity — Direção Geral de Alimentação e
Veterinária.
2.2. Animal treatments
Twelve-week-old male C57BL/6J mice were purchased from Charles
River and housed in groups of 4 or 5 animals in filter-topped poly-
sulfone cages in a conventional animal facility. All animals were
maintained under standard laboratory conditions: an artificial 12 h
light/dark cycle, with an ambient temperature of 21 ± 1 °C and a re-
lative humidity of 50–60%; the mice were given a standard diet and
water ad libitum. Health monitoring was performed according to
FELASA guidelines (Nicklas et al., 2002; Guillen, 2012). Humane end-
points for experiments were defined (20% reduction of the body
weight, inability to reach food and water, presence of wounds in the
body, dehydration), but not needed in practice, as animals did not reach
these endpoints in the study period.
Mice were intraperitoneally (i.p.) injected once with MPTP (Sigma
Aldrich), with a dose of 40mg/kg body weight. This represents an acute
MPTP paradigm used as an experimental model of drug-induced par-
kinsonism. This was previously shown by us and others to accurately
recapitulate time-dependent analysis of nigro-striatal neuroadaptive
changes (Jackson-Lewis et al., 1995; Saporito et al., 2000; Jackson-
Lewis and Przedborski, 2007; Castro-Caldas et al., 2009; Rosa et al.,
2018). TUDCA (Sigma Aldrich) was administered daily i.p. at a dose of
50mg/kg body weight, for 3 consecutive days, as previously described
(Keene et al., 2001; Castro-Caldas et al., 2012).
Mice designated for the short-term treatment were divided in 4
groups (6 mice per group): i) mice that received saline (Control, C); ii)
mice injected with MPTP and euthanized 3 h after MPTP administration
(MPTP); iii) mice that received daily injection of TUDCA during 3
consecutive days, followed by i.p. administration of MPTP on day 3, 6 h
after the last TUDCA injection, and that were euthanized 3 h after MPTP
administration (TUDCA+MPTP); iv) mice injected with MPTP, fol-
lowed by 3 daily injections of TUDCA starting 3 h after the neurotoxin
administration and were euthanized 6 h after the last TUDCA admin-
istration (MPTP+TUDCA).
Mice evaluated in the long-term treatment were also divided in 4
groups (6 mice per group): i) mice that received saline (Control, C); ii)
mice injected with MPTP and euthanized 52 days after MPTP admin-
istration (MPTP); iii) mice that received daily injection of TUDCA
during 3 consecutive days, followed by i.p. administration of MPTP on
day 3, 6 h after the last TUDCA injection, and that were euthanized
52 days after MPTP administration (TUDCA+MPTP); iv) mice injected
with MPTP, followed by 3 daily injections of TUDCA starting 3 h after
the neurotoxin administration and were euthanized 52 days after MPTP
injection (MPTP+TUDCA).
Treatments were carried out in at least 4 independent experiments
(n= 4) for short- and long-term evaluation experiences.
After treatments, mice were decapitated, under anesthesia with
sodium pentobarbital (50mg/kg, i.p.), and the cerebral cortex was
isolated at the level of the nigro-striatal axis (Bregma −3.20 to 1.00).
Cortex region samples were stored at −80 °C until further use.
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2.3. Culture conditions and cells treatments
In vitro studies were carried out using the immortalized murine
microgial cell line BV2 (ATCC). Cells were maintained in RPMI 1640
medium supplemented with 10% FBS and 1% of Penicillin/strepto-
mycin, at 37 °C in a humidified atmosphere of 5% CO2, in HERAcell 150
incubators (Thermo Scientific, Waltham, MA, USA). Cells (1× 106)
were plated in 60mm culture dishes and left to stabilize for 24 h prior
to treatment with 100 μM of TUDCA for different time points (3, 6 or
24 h). In another set of experiments BV2 cells were pre-treated with
5 μM of H89 (an inhibitor of protein kinase A, PKA) for 1 h, and then
with 100 μM of TUDCA for 3 or 6 h more. Controls were always in-
cluded, and consisted of treating the cells with vehicle. Treatments
were carried out in at least three independent experiments.
2.4. Preparation of protein extracts
Mice cortex protein extracts were prepared as previously described
(Rosa et al., 2018).
After treatments, BV2 cells were washed with ice-cold PBS supple-
mented with or without 1mM of EDTA in order to seize extracellular
ANXA1 (Castro-Caldas et al., 2003), or for preparation of total cell
extracts, respectively. Subsequently, the preparation of intracellular or
total cell extracts cells followed a previously described protocol (Rosa
et al., 2017).
Total protein concentration was determined using Bio-Rad's Protein
Assay Reagent, according to the manufacturer's instructions.
2.5. Measurement of ATP levels
ATP levels were measured in samples of mice cortex tissue extracts
with the ATP-Glo™ Bioluminometric Cell Viability Assay (Biotium,
Hayward, CA, USA), according to the manufacturer's instructions. The
Luciferase activity in each sample was then measured in a luminometer
(Berthold Systems). Negative controls were always included, and results
were normalized to the total protein concentration in each well, as
previously described (Rosa et al., 2017).
2.6. Western blot analysis
Protein extracts, from mice cortex or BV2 cells were separated in
SDS-PAGE and electrotransfered to activated Immobilon P membranes
(Millipore, Bedford, MA, USA).
The membranes were then blocked with 5% non-fat dry milk in TBS-
T 0.1%, and then incubated with the specific primary antibodies de-
picted in Table 1, overnight at 4 °C with agitation. Next, membranes
were incubated with horseradish peroxidase-conjugated anti-mouse or
anti-rabbit (Bio-Rad), or anti-Armenian hamster (Santa Cruz) secondary
antibodies, for 1 h at r.t. The immunocomplexes were visualized by
chemiluminescent detection with SuperSignal® West Femto Maximum
Sensivity Substrate in a ChemiDoc™ MP imaging system from Bio-Rad
Laboratories. After the evaluation of the different proteins, membranes
were stripped and then incubated with anti-β-actin primary antibody as
a loading control.
The relative intensities of protein bands were analyzed with Image
Lab TM analysis software (Bio-Rad Laboratories, Hercules, CA, USA)
and results were normalized to the percentage of control.
2.7. Immunohistochemistry
Cryostat coronal sections at the level of midstriatum and SNpc were
prepared as previously described (Rosa et al., 2018). Incubation with
primary antibodies anti-Ionized calcium binding adaptor molecule 1
(Iba-1) or anti-Glial fibrillary acidic protein (GFAP) (Table 1) was
performed overnight at 4 °C, followed by incubation with the anti-
rabbit Alexa Fluor® 488 secondary antibody (ThermoFisher Scientific),
1 h at r.t. Sections were observed under an Axioskop microscope (Carl
Zeiss) with an attached Leica DFC490 camera, and photographed using
Image Manager 50 software (Leica Microsystems, Inc.). Green (for both
GFAP and Iba-1) and blue (for nuclei) fluorescence and UV images of, at
least, 15 random microscopic fields belonging to mice cerebral cortex
region, were acquired per slice, under 400× magnification. The results
were expressed as the percentage of area occupied by GFAP or Iba-1
positive cells, measured by using the ImageJ software analysis (Na-
tional Institutes of Health, USA).
Control experiments for nonspecific binding were performed in
parallel by omission of the primary antibody.
2.8. Statistical analysis
All results are expressed as mean ± SEM values. Data were ana-
lyzed by Student's t-test (2 groups), or one way ANOVA (>2 groups)
and differences between groups were determined by post hoc
Bonferroni's test, whereas comparison of treatments to the control was
performed by post hoc Dunnett's test, using GraphPad Prism 6.0 (San












































Fig. 1. ATP and p-AMPK levels in the cortex of
MPTP-treated mice. Animals were treated with ve-
hicle, MPTP, TUDCA prior to MPTP (TUDCA+MPTP)
or TUDCA after MPTP (MPTP+TUDCA), and were
euthanized 52 days post-MPTP administration. (A)
ATP levels were quantified in cortex extracts. (B)
Levels of p-AMPK were determined in the cortex by
Western blot analysis. β-Actin was used as loading
control. Relative band intensity was quantified using
the Image Lab™ software and expressed as a percen-
tage of control. Data represent mean values ± SEM
of at least three independent experiments, indicated
as percentage of control. *p < 0.05, **p < 0.01 and
***p < 0.001 using one-way ANOVA with
Bonferroni's post hoc test.
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3. Results
3.1. Effect of TUDCA on ATP levels and AMPK phosphorylation in the
cortex of MPTP-treated mice
To characterize the effects triggered by MPTP in the cortex, we
determined ATP levels in mouse cortical extracts (Fig. 1A). As expected,
upon a short-term treatment with MPTP we could not observe any
changes in ATP levels in any condition studied (data not shown).
However, at 52 days after MPTP injection there was a significant de-
crease of ATP levels as compared to controls. Importantly, pre-treat-
ment with TUDCA prevented the decrease of ATP levels found in MPTP-
exposed animals. Mice that were post-treated with TUDCA showed ATP
levels similar to those found in MPTP-injected animals.
To further evaluate the putative protective role of TUDCA on the
ATP deficit induced by MPTP, we evaluated the phosphorylation levels
of the energy sensor AMP-activated protein kinase (AMPK) (Fig. 1B).
No changes in p-AMPK levels could be observed 3 h after MPTP ad-
ministration (data not shown). Interestingly, results show that in the
cortex of MPTP-injected animals for 52 days the levels of activated
AMPK (p-AMPK) were significantly lower than in control mice. p-AMPK
levels were significantly increased in animals treated with TUDCA be-
fore MPTP compared to MPTP alone. However, post-treatment with
TUDCA did not change the phosphorylation status of AMPK.
3.2. Effect of TUDCA on antioxidant enzymes in the cortex of MPTP-
treated mice
To evaluate whether treatment with MPTP/TUDCA was able to af-
fect the expression of enzymes involved in the antioxidant response in
the cortex of MPTP mice, we determined the levels of Glutathione
peroxidase (GPx) and Heme oxygenase-1 (HO-1) in cortical extracts
(Fig. 2). In animals euthanized 3 h post-MPTP administration (short-
term treatment), the levels of GPx were significantly increased in MPTP
and in TUDCA+MPTP treated mice (Fig. 2A). However, when animals
were euthanized 52 days after MPTP administration (long-term treat-
ment) the increase in GPx expression was only maintained in animals
pre-treated with TUDCA (Fig. 2B). HO-1 expression followed a trend
similar to GPx after MPTP administration. However, pre-treatment with
TUDCA significantly up-regulated HO-1 levels in short-term treatment,
and preserved HO-1 concentration significantly higher than that ob-
served in MPTP animals, in long-term experiments (Fig. 2A, B). Inter-
estingly, although post-treatment with TUDCA at the longer time-point
significantly decreases GPx expression, HO-1 expression remained high
in these animals, suggesting different ways of activation for both en-
zymes.
3.3. Effect of TUDCA on parkin levels in the cortex of MPTP mice
We have previously shown that pre-treatment with TUDCA pro-
motes mitophagy in MPTP-insulted mice via the E3 protein-ubiquitin
ligase parkin (Rosa et al., 2017). Here we evaluated the effect of
TUDCA, either before or after MPTP administration, on parkin expres-
sion in the cortex of animals euthanized 3 h or 52 days after MPTP in-
jection. Results presented in Fig. 3A show that at shorter time-points,
MPTP induced a significant increase in parkin levels. Post-treatment
with TUDCA induced an increase of parkin similar to MPTP only,
whereas pre-treatment with TUDCA exacerbated this increase. Up-reg-
ulation of parkin levels in response to MPTP seems to be a transient
event, since at day 52 after MPTP administration only in animals that
were pre-treated with TUDCA parkin protein levels were maintained
significantly higher.
3.4. Role of TUDCA on MPTP-induced neuroinflammation in the cortex
Glial activation in the cortex was evaluated in animals euthanized
52 days after MPTP injection by determination of GFAP (Fig. 4A) or Iba-
1 (Fig. 4B) expression, markers for astrogliosis and microgliosis, re-
spectively. In the cortex of MPTP-injected mice, in the presence or
absence of TUDCA, GFAP and Iba-1 expression were significantly in-
creased. Importantly, astrocyte activation was partially prevented in
animals pre- or post-treated with TUDCA (Fig. 4A), whereas pre-treat-
ment (but not post-treatment) with TUDCA partially prevented MPTP-
induced Iba-1 expression (Fig. 4B).
To better evaluate the role of MPTP and/or TUDCA on neuroin-
flammation, levels of the pro-inflammatory cytokine interleukin-1β (IL-
1β) (Fig. 4C) and of the anti-inflammatory protein ANXA1 (Fig. 4D)
were determined by Western blot in cortex samples from these animals.
Results show that IL-1β expression levels were significantly increased in
MPTP animals, and that this increase was prevented by TUDCA
Fig. 2. TUDCA increases levels of anti-
oxidant enzymes in the cortex of MPTP-
treated mice. Mice were treated with ve-
hicle, MPTP, TUDCA prior to MPTP
(TUDCA+MPTP) or TUDCA after MPTP
(MPTP+TUDCA), and were euthanized 3 h
(Short-term treatment) (A) or 52 days (Long-
term treatment) (B) post-MPTP administra-
tion. Antioxidant enzymes GPx and HO-1
were evaluated by Western blot analysis in
the cortex extracts. β-Actin was used as
loading control. Representative im-
munoblots are presented for each protein.
Relative band intensity was quantified using
the Image Lab™ software and expressed as a
percentage of control. Data shown are mean
values ± SEM of at least three independent
experiments. *p < 0.05, and ***p < 0.001
using one-way ANOVA with Bonferroni's
post hoc test.
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administration either before or after administration of the neurotoxin.
On the other hand, ANXA1 expression levels were significantly in-
creased in animals treated with TUDCA prior to or after MPTP injection.
Together, these results show that MPTP induces a pro-inflammatory
response in the cortex that is efficiently ameliorated when animals are
treated with TUDCA either before or after the neurotoxin administra-
tion.
3.5. TUDCA modulation of ANXA1 expression in BV2 microglia cell line
Our results show that neuroinflammation is a striking outcome of
MPTP effects on mice cerebral cortex. We have also found that TUDCA
treatment is, at least partially protective, by significantly decreasing
neuroinflammation. ANXA1 seems to be an interesting target of TUDCA
anti-inflammatory action. In order to further explore the mechanism by
which this bile acid modulates ANXA1 expression we have used an in
vitro glial cell model. Since in the brain ANXA1 is found to be almost
exclusively expressed in glial cells and mainly in microglia (Solito et al.,
2008), here we used the BV2 microglia cell line. In addition to evalu-
ating intracellular levels of ANXA1, we also determined membrane-
bound extracellular levels, considering the extracellular role of this
protein in inflammatory processes. The intra- and extracellular levels of
ANXA1 in response to treatment with TUDCA were evaluated at dif-
ferent time-points. Intracellular ANXA1 protein levels (Fig. 5A) were
significantly higher 6 h after TUDCA administration. Interestingly, the
extracellular levels of ANXA1 were also significantly increased after 6 h
exposure to TUDCA (Fig. 5B). Together these results indicate that
TUDCA induces the secretion of ANXA1 and replenishes the in-
tracellular content of the protein, strongly suggesting de novo synthesis
of ANXA1. Since the peak of intra- and extracellular protein was found
at 6 h post-TUDCA addition, this time-point was used in the subsequent
experiments aiming to determine the mechanisms underlying the
modulation of ANXA1 expression by TUDCA.
3.6. Unraveling the mechanism underlying the modulation of ANXA1 by
TUDCA
The promotor region of ANXA1 gene contains a cAMP responsive
element (CRE) that requires an activated CRE binding protein (CREB) to
induce ANXA1 mRNA synthesis (Antonicelli et al., 2001). CREB acti-
vation occurs upon its phosphorylation, a process regulated by several
signaling pathways. cAMP is thought to play a critical role in this
process, since production of this secondary messenger activates PKA,
which is responsible for CREB phosphorylation (Hagiwara et al., 1993).
Taking this into account, and together with the fact that TUDCA in-
creases cAMP levels in primary cultures of microglia cells (Yanguas-
Casas et al., 2017), we evaluated whether the activation of PKA
pathway by TUDCA is involved in ANXA1 increased synthesis, using a
specific pharmacological inhibitor of this kinase (H89). TUDCA treat-
ment increased the levels of activated PKA (p-PKA), which were sig-
nificantly prevented by pre-treatment with H89 (Fig. 5C). Both PKA and
protein kinase B (AKT) have been implicated in CREB activation (Peltier
et al., 2007). We already demonstrated that TUDCA modulates AKT
activation in several models of disease, which is important for its
neuroprotective effect (Solá et al., 2003; Castro et al., 2004; Castro-
Caldas et al., 2012). Here, we confirmed that TUDCA increased p-AKT
levels in microglia, particularly at 6 h post-TUDCA (Fig. 5D), further
corroborating the ability of TUDCA to modulate this pathway in dif-
ferent cellular contexts. Accordingly to the above, TUDCA increased the
levels of p-CREB in a time-dependent manner, being statistically dif-
ferent at 6 h of treatment, indicating activation of this transcription
factor. As expected, pre-treatment with H89 prevented the TUDCA-in-
duced increase in p-CREB levels (Fig. 5E). Finally, the expression levels
of total ANXA1 were significantly decreased when cells were treated
with H89 prior to TUDCA (Fig. 5F). These results strongly suggest that
TUDCA up-regulates ANXA1 expression in microglia through the acti-
vation of the PKA-CREB pathway.
In conclusion, in vitro results show that TUDCA modulates synthesis
of ANXA1 in microglia cells, reinforcing the results obtained in mice
cortex, and suggest that the anti-inflammatory effect of TUDCA may be,
at least partially, mediated by ANXA1.
4. Discussion
The most vulnerable region in PD is considered to be the nigro-
striatal axis and only a very limited number of studies have described
PD damage progression in regions such as cerebral cortex (Cassarino
et al., 1997; Fahn, 2003; Garcia-Esparcia et al., 2018; Becker et al.,
2018), which is essential to address the development of new and more
efficient therapeutic strategies.
Previous works showed that in early stages of the disease, neuron
loss is confined to the ventrolateral substantia nigra leaving other
midbrain areas exempts, though it becomes more widespread by the
end-stage of the disease, corroborating that neurodegeneration and
Fig. 3. TUDCA modulates the expression of
parkin in the cortex of mice treated with
MPTP. Mice were treated with vehicle,
MPTP, TUDCA prior to MPTP
(TUDCA+MPTP) or TUDCA after MPTP
(MPTP+TUDCA), and were euthanized 3 h
(Short-term treatment) (A) or 52 days (Long-
term treatment) (B) post-MPTP administra-
tion. Representative immunoblots and re-
spective quantification of parkin in cortex
extracts are shown. β-Actin was used as
loading control. Relative band intensity was
quantified using the Image Lab™ software
and expressed as a percentage of control.
Data represent mean values ± SEM of at
least three independent experiments, in-
dicated as percentage of control. *p < 0.05,
**p < 0.01 and ***p < 0.001 using one-
way ANOVA with Bonferroni's post hoc test.
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Lewy bodies formation are not only restricted to dopaminergic neurons
but also affect noradrenergic, serotonergic and cholinergic systems, as
well as the cerebral cortex, olfactory bulb, and autonomic nervous
system in PD (Dauer and Przedborski, 2003; Poewe et al., 2017).
Indeed, in the MPTP-induced parkinsonism there is a major loss of
serotonin and norepinephrine innervations of the cortex, which may
account for the depression symptoms occurring in PD (Nayyar et al.,
2009).
Fig. 4. TUDCA modulates glial activation and
ANXA1 expression in the cortex of MPTP-
treated mice. Fluorescence microscopy images
showing GFAP (A) and Iba-1 (B) staining in
the cortex of mice treated with vehicle (con-
trol), MPTP, TUDCA prior to MPTP
(TUDCA+MPTP) or TUDCA after MPTP
(MPTP+TUDCA), euthanized 52 days post-
MPTP administration. GFAP and Iba-1 are
stained in green and nuclei are counterstained
with the Hoechst dye 33258. Scale
bar= 10 μm. The area occupied by GFAP or
Iba-1 positive cells was measured using the
ImageJ software, and is expressed as percen-
tage of control. Representative immunoblot of
IL-1β (C) or ANXA1 (D) in cortex samples from
mice treated with vehicle (control), MPTP,
TUDCA prior to MPTP (TUDCA+MPTP) or
TUDCA after MPTP (MPTP+TUDCA), eu-
thanized 52 days post-MPTP administration.
β-Actin was used as loading control. Relative
band intensity was quantified using the Image
Lab™ software and expressed as a percentage
of control. Data shown are mean
values ± SEM of at least three independent
experiments. *p < 0.05, **p < 0.01 and
***p < 0.001 using one-way ANOVA with
Bonferroni's post hoc test. (For interpretation
of the references to colour in this figure le-
gend, the reader is referred to the web version
of this article.)
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Increased expression of oxidative stress markers as well as impair-
ment of complex I function were found in cerebral cortex of PD patients
(Navarro and Boveris, 2009; Harish et al., 2013; Garcia-Esparcia et al.,
2018). Accordingly, adaptive responses including increases in anti-
oxidant enzymes have also been reported in the cortex after MPTP
treatment (Cassarino et al., 1997), and cortical dopaminergic de-
nervation has been recently reported in the 6-hydroxydopamine (6-
OHDA) PD model (Becker et al., 2018).
Here we investigated whether the deleterious effects of MPTP in the
mouse brain are also observed in the cerebral cortex. In parallel, we
investigated the protective effect of TUDCA in the cortex of mice ex-
posed to MPTP, and in microglia cells.
As an outcome of the neurotoxic/neuroprotective effects of MPTP/
TUDCA in the cerebral cortex, we investigated ATP levels and AMPK
activation, as well as endogenous cellular defense mechanisms against
oxidative stress. Interestingly, the results presented here recapitulate
our previous observations in mice midbrain and striatum (Rosa et al.,
2018; Rosa et al., 2017; Moreira et al., 2017), showing that cerebral
cortex is also affected in this PD model. In fact, ATP levels were sig-
nificantly decreased in MPTP treated mice. Moreover, in the short-term
treatment, exposure to MPTP and/or treatment with TUDCA increased
protein levels of HO-1, GPx1 and parkin. The fact that MPTP by itself
up-regulated the expression of these enzymes may indicate a possible
compensatory mechanism in response to MPTP-induced oxidative
stress, which has already been reported by us in midbrain and striatum
(Carvalho et al., 2016; Moreira et al., 2017; Rosa et al., 2017) and by
others in the cortex (Cassarino et al., 1997). However, at longer time
points increased expression of GPx, HO-1 and parkin were only sus-
tained when animals were pre-treated with TUDCA, since these en-
dogenous adaptive responses triggered after short-term treatment are
probably not sufficient nor adequate to overcome the neurodegenera-
tive pathways activated by MPTP. Accordingly, we found that pre-
treatment with TUDCA also prevented the decrease in ATP levels and
promoted AMPK activation. Therefore, pre-treatment with TUDCA not
only exacerbates the cytoprotective adaptive responses, but also ex-
tends their expression/activation throughout time. These mechanisms
may “buffer” the cytotoxic effects of MPTP taking advantage of en-
dogenous pathways, probably responsible for the neuroprotection af-
forded by this bile acid in the presence of the neurotoxin. These results
also highlight the potential of TUDCA as a neuroprotective agent in
different cerebral regions, confirming its putative beneficial effect in
PD.
To further explore the role of TUDCA in the cerebral cortex, we also
investigated its anti-inflammatory effect. As expected, we show an
Fig. 5. TUDCA increases ANXA1 expression and secretion in the mouse microglia cell line BV2. Cells were treated with TUDCA for different time-points and
extracellular ANXA1 was obtained after washing the cells with 1mM EDTA buffer, as described in Methods. Intracellular extracts (A) and products of EDTA buffer
wash (membrane-bound extracellular protein) (B) were subjected to SDS-PAGE, and the blots were probed with antibodies against ANXA1, and β-actin or amido
black as loading controls. To evaluate the involvement of the PKA pathway on ANXA1 expression triggered by TUDCA, cells were treated with TUDCA in the presence
or absence of the PKA inhibitor H89. Cell extracts were subjected to SDS-PAGE, and the blots were probed with antibodies against p-PKA (C), p-AKT (D), p-CREB (E)
or ANXA1 (F). β-actin was used as a loading control. Relative band intensity was quantified using the Image Lab™ software and expressed as a percentage of control.
Data shown are mean values ± SEM of at least three independent experiments. *p < 0.05 using T-student test (B). *p < 0.05, **p < 0.01 and ***p < 0.001 using
one-way ANOVA with Dunnett's (A, D) or Bonferroni's (C, E and F) post hoc tests.
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increased expression of astro- and microgliosis markers in mice cortex,
namely GFAP and Iba-1, respectively, in the presence of MPTP, which is
consistent with previous results in the nigro-striatal axis (Rosa et al.,
2018; Khan et al., 2013; Lofrumento et al., 2011). Notably, TUDCA
treatment decreased the number of GFAP- positive cells, particularly
when it was administrated before MPTP. Pre-treatment with TUDCA
was also effective in preventing microglia activation, as demonstrated
by decreased number of Iba-1 positive cells. Additionally, we show that
MPTP increased the expression of IL-1β in mice cortex, which was
prevented by pre- or post-treatment with TUDCA. Importantly, our
results also show increased ANXA1 expression, when animals were
treated with TUDCA either before or after MPTP. Together these results
support the anti-inflammatory effect of TUDCA previously described by
our group in midbrain and striatum from MPTP-treated mice (Rosa
et al., 2018), and by Yanguas-Casas and colleagues in a model of acute
neuroinflammation (Yanguas-Casas et al., 2014, 2017).
ANXA1 is an anti-inflammatory protein that in the brain is mostly
expressed in microglia cells (de Coupade et al., 2000; McArthur et al.,
2010; Solito et al., 2001). Moreover, extracellular ANXA1 has been
reported to play a role in anti-inflammatory processes, making the se-
cretion of this protein a possible indicator of a pro-resolving response
mediated by ANXA1 (Buckingham and Flower, 1997; Fan et al., 2004;
Flower, 1988).
Here we further explored the mechanisms underlying TUDCA
modulation of ANXA1 expression using a microglia cell line. The pro-
motor region of ANXA1 gene contains a CRE that can be induced by
increased levels of cAMP (Antonicelli et al., 2001; Castro-Caldas et al.,
2003; Lima et al., 2017). Interestingly, TUDCA has been shown to
mediate anti-inflammatory effects on microglia upon lipopoly-
saccharide (LPS) administration through activation of the G protein-
coupled bile acid receptor 1/Takeda G protein-coupled receptor 5
(GPBAR1/TGR5), with consequent increases of intracellular cAMP le-
vels (Yanguas-Casas et al., 2017). Here, we show that TUDCA sig-
nificantly increased secreted and intracellular levels of ANXA1 in BV2
cells. The up-regulation of ANXA1 secretion, together with de novo
synthesis of this protein reveals one possible mechanism by which
TUDCA exerts its anti-inflammatory effects, and may explain the results
obtained in mouse brain. In dissecting the mechanisms underlying
TUDCA modulation of ANXA1 expression, our results show an up-reg-
ulation of phosphorylated PKA and CREB transcription factor in cells
exposed to TUDCA. Accordingly, we demonstrate a decrease in ANXA1
expression levels in cells that were pre-incubated with the PKA in-
hibitor, H89. Besides PKA, AKT has also been implicated in CREB ac-
tivation (Peltier et al., 2007), and we demonstrate that TUDCA sig-
nificantly up-regulates p-AKT levels. Activation of AKT by TUDCA has
already been described by us and others in several cells and models of
neurodegenerative diseases and has been associated with its cytopro-
tective role (Solá et al., 2003; Castro et al., 2004; Castro-Caldas et al.,
2012). To our knowledge AKT activation by TUDCA in microglia has
never been demonstrated, and further highlights the anti-inflammatory
effects of this bile acid. Since PKA and AKT are possible upstream
regulators of CREB activation, our data may unveil a pathway re-
sponsible for TUDCA regulation of ANXA1 expression that needs to be
further explored in vivo, and from a mechanistic point of view.
Other works indicate a time-dependent induction of responses from
the nigro-striatal axis to the cerebral cortex. Interestingly, and sur-
prisingly, we found that some of the neuroprotective adaptive responses
elicited by MPTP were detected in the same time-points in the nigro-
striatal axis and in the cerebral cortex. This is the case for GPx1, HO-1
and parkin. On the other hand, ANXA1 expression was not altered in
short-term treatment in the cerebral cortex (data not shown). Moreover,
in the cortex GFAP and Iba-1 expression were only increased after long-
term treatment with MPTP. Together these findings indicate that dif-
ferent end points have different activation courses in the cerebral cortex
and nigro-striatal axis. They also show that the inflammatory reaction is
detected at later time-points in the cerebral cortex.
Therefore, our understanding of the disease pathogenic mechanisms
should involve a broader analysis of the brain. This study may be a
contribution to this emerging approach, adding some new insights to
the still scarce data available. In parallel we demonstrate a potential
role for ANXA1 upregulation as an anti-inflammatory strategy induced
by TUDCA, even though additional work needs to be done to under-
stand the molecular mechanisms involved in this process.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.mcn.2019.01.003.
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